MOLECULAR GENETIC CHANGES AS A MARKER FOR THE EFFICIENCY OF TREATMENT FOR GASTRIC CANCER


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The use of molecular genetic markers associated with the course and prognosis of the disease, a response to performed therapy, and the risk of side effects will assist in elaborating an individualized approach to treating patients with gastric cancer.

全文:

受限制的访问

作者简介

A. Chernousov

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

M. Nemtsova

Research Center of Medical Genetics, Russian Academy of Medical Sciences, Moscow

Email: vichy@list.ru

T. Khorobrykh

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

A. Udilova

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

D. Vychuzhanin

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

R. Nurutdinov

I.M. Sechenov First Moscow State Medical University

Email: vichy@list.ru

参考

  1. Скоропад В.Ю. Рациональная тактика лечения местно-распространенного рака желудка: место лучевой терапии // Практ. онкол. - 2009; 1: 28-35.
  2. Whiting J., Sigurdsson A., Rowlands D. еt al. The long term results of endoscopic surveillance of premalignant gastric lesions // Gut. - 2002; 50: 378-81.
  3. Yoshino K., Hirakava K., Nakajima T. еt al. Meeting report of the 74th Congress of the Japanese Gastric Cancer Association // Gastric. Cancer. - 2002; 5: 185-93.
  4. Hamilton S., Altonen L. World Health Organization classification of tumours. Pathology an genetics of tumours of the digestive system / Lyon, 2005; p. 314.
  5. Пальцев М.А., Залетаев Д.В. Системы генетических и эпигенетических маркеров в диагностике онкологических заболеваний / М.: ОАО «Издательство «Медицина», 2009; 384 с.
  6. Japanese Classification of Gastric Cancer. 2nd English Edition. JGCA // Gastric. Cancer. - 1998; 1 (1): 10-24.
  7. Japanese Research Society for Gastric Cancer. The General Rules for the Gastric Cancer Study in Surgery and Pathology // Jpn. J. Surg. - 1981; 11 (2): 127-39.
  8. Sawai K., Takahashi T., Suzuki H. New trends in surgery for gastric cancer in Japan // J. Surg. Oncol. - 1994; 56: 221-6.
  9. Maruyama K., Sasako M., Kinoshita T. et al. Can sentinel node biopsy indicate rational extent of lymphadenectomy in gastric cancer surgery? Fundamental and new information on lymph node dissection // Langenbeck’s Arch. Surg. - 1999; 384: 149-57.
  10. Shimoyama S. Current treatment Strategies for Early Gastric Cancer. The Diversity of Gastric Carcinoma. 2005; 253-70.
  11. Cuschieri A., Weeden S., Fielding J. et al. Patient survival after D1 and D2 resection for gastric cancer: long-term results of the MRC randomized surgical trial. // Br. J. Cancer. - 1999; 79: 1522-30.
  12. Bonenkamp J., Hermans J., Sasako M. et al. Extended lymph node dissection for gastric cancer // N. Engl. J. Med. - 1999; 340: 908-14.
  13. Kurita A., Takashima S., Takayama T. et al. Intraperitoneal chemotherapy for gastric carcinoma combined with peritoneal dissemination by intraperitoneal catheter with a subcutaneous reservoir // Jpn. J. Cancer Chemother. - 1994; 21 (14): 2439-44.
  14. Kang Y., Choi D., Im Y. et al. A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer // Proc. ASCO. - 1996; 15: 215.
  15. Неред С.Н., Клименков А.А., Стилиди И.С. и др. Хирургическое и комбинированное лечение больных раком желудка с высоким риском имплантационного метастазирования // Вопр. онкол. - 2005; 1: 75-80.
  16. Yonemura Y. A new treatment strategy for peritoneal dissemination -peritonectomy intraoperative chemohyperthermia and EPIC. 4th International gastric cancer congress. New York, 2001 April 29-May 2; p. 335.
  17. Fujimoto S., Takahashi M., Mutou T. et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma // Cancer. - 1999; 85: 529-34.
  18. Hirose K., Katayama K., Iida A. et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. // Oncology. - 1999; 57: 106-14.
  19. Li Q., Ito K., Sakakura C. et al. Causal relationship between the loss of RUNX3 expression and gastric cancer // Cell. - 2002; 109: 113-24.
  20. Hong S., Jeon E., Oh J. et al. The gene-reduction effect of chromosomal losses detected in gastric cancers // BMC Gastroenterology. - 2010; 10: 138.
  21. Ottini L., Falchetti M., Lupi R. et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives // Ann. Oncol. - 2006; 17 (7): 97-102.
  22. Yashiro M., Inoue T., Nishioka N. Allelic Imbalance at p53 Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcimoma // Ann. Surg. Oncol. - 2009; 16 (10): 2926-35.
  23. Grundei T., Vogelsang H., Ott K. et al. Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma // Clin. Cancer Res. - 2000; 6: 4782-8.
  24. Ott K., Vogelsang H., Mueller J. et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma // Clin. Cancer Res. - 2003; 9 (6): 2307-15.
  25. Иванов В.И., Киселев Л.Л. Геномика в медицине / М.: Академкнига, 2005.
  26. Kristensen M., Pedersen P., Melsen G. et al. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients // J. Int. Med. Res. - 2010; 38 (3): 870-83.
  27. Ishida Y., Kawakami K., Tanaka Y. et al. Association of thymidylate synthase gene polymorphism with its mRNA and protein expression and with prognosis in gastric cancer // Anticancer Res. - 2002; 22: 2805-9.
  28. Jackman A., Calvert A. Folate-based thymidylate synthase inhibitors as anticancer drugs // Ann. Oncol. - 1995; 6 (9): 871-81.
  29. Zhang Q., Zhao Y., Liao Q. et al. Associations between gene polymorphisms of thymidylate synthase with its protein expression and chemosensitivity to 5-fluorouracil in pancreatic carcinoma cells // Chin. Med. J. (Engl.). - 2011; 124 (2): 262-7.
  30. Баранов В.С., Баранова Е.В., Иващенко Т.Э. и др. Геном человека и гены «предрасположенности». Введение в предиктивную медицину / СПб, 2000; 55 с.
  31. Блохина Е.Б. Роль полиморфизма ферментов цикла фолиевой кислоты (MTHFR, TS) в развитии острого лимфобластного лейкоза // Педиатрия. -2004; 12: 69-71.
  32. Farina-Sarasqueta A., Gosens M., Moerland E. et al. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients // Anal. Cell. Pathol. (Amst.). - 2010; 33 (1): 1-11.
  33. Ulrich C., Bigler J., Velicer C. et al. Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene // Cancer Epidemiol. Biomarkers Prev. - 2000; 9: 1381-5.
  34. Mandola M., Stoehlmacher J., Zhang W. et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels // Pharmacogenetics. - 2004; 14: 319-27.
  35. Xu Y., Yao L., Ouyang T. et al. P53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer // Clin. Cancer Res. - 2005; 11: 7328-33.
  36. Toyama T., Zhang Z., Nishio M. et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients // Breast Cancer Res. - 2007; 9: R34.
  37. Wu X., Zhao H., Amos C. et al. P53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity // J. Natl. Cancer Inst. - 2002; 94: 681-90.
  38. Sayhan N., Yazici H., Budak M. et al. P53 codon 72 genotypes in colon cancer. / Association with human papillomavirus infection // Res. Commun. Mol. Pathol. Pharmacol. - 2001; 109: 25-34.
  39. Buyru N., Altinisik J., Demokan S. et al. P53 genotypes and haplotypes associated with risk of breast cancer // Cancer Detect. Prev. - 2007; 31: 207-13.
  40. Lancaster J., Brownlee H., Wiseman R. et al. P53 polymorphism in ovarian and bladder cancer // Lancet. - 1995; 346: 182.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2014
##common.cookie##